Next-generation endocrine therapy in HR+/HER2 - breast cancer: oral SERDs, ER-targeting innovations, and ctDNA-driven ESR1 mutation-guided switching.

doi:10.1007/s12282-026-01900-0

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Next-generation endocrine therapy in HR+/HER2 - breast cancer: oral SERDs, ER-targeting innovations, and ctDNA-driven ESR1 mutation-guided switching.

Breast cancer (Tokyo, Japan) - 1 Sept 2026

Yao Nan, Xu Guoshuai, Duan Ning, Han Fuzhou, Li Wenqiang, Qu Jun

Abstract excerpt

BACKGROUND: Endocrine therapy (ET) is the backbone of HR+/HER2 - breast cancer management, yet acquired resistance commonly emerges despite aromatase inhibitors (AIs) and CDK4/6 inhibitors. A key actionable mechanism is treatment-selected ESR1 mutation, detectable in circulating tumor DNA (ctDNA) before radiographic progression. SCOPE OF REVIEW: This narrative review summarizes (i) next-generation estrogen...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Antineoplastic Agents, Hormonal
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Estrogen Receptor alpha

Share to Molecular Targeted Therapy

Share to Receptors, Progesterone

Source

Open in PubMed

Identifiers

PMID: 42565973
DOI: 10.1007/s12282-026-01900-0

Genes

ESR1
CDK4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.